TipRanks
Advertisement
Advertisement

OCGN Stock Latest News

Largest borrow rate increases among liquid names
The FlyLargest borrow rate increases among liquid names
6h ago
APLX
CSIQ
Ocugen Adjourns Special Meeting on Authorized Share Increase
PremiumCompany Announcements
Ocugen Adjourns Special Meeting on Authorized Share Increase
6d ago
8K
OCGN
Analyst Maintains Buy Rating on Ocugen as OCU400’s Early Revenue Pathway and Phase 3 Upside Support Unchanged $11 Price Target
PremiumRatings
Analyst Maintains Buy Rating on Ocugen as OCU400’s Early Revenue Pathway and Phase 3 Upside Support Unchanged $11 Price Target
12d ago
OCGN
Ocugen’s OCU400 granted provisional approval, priority designation from LARTA
PremiumThe Fly
Ocugen’s OCU400 granted provisional approval, priority designation from LARTA
17d ago
OCGN
Ocugen Stockholders Approve Meeting Adjournment for Share Increase
PremiumCompany Announcements
Ocugen Stockholders Approve Meeting Adjournment for Share Increase
19d ago
8K
OCGN
Ocugen: Buy Rating Maintained as Analyst Sees Upside Potential in OCU410ST Trial and Keeps $8 Price Target Unchanged
PremiumRatingsOcugen: Buy Rating Maintained as Analyst Sees Upside Potential in OCU410ST Trial and Keeps $8 Price Target Unchanged
26d ago
OCGN
Ocugen price target lowered to $9.50 from $10 at H.C. Wainwright
Premium
The Fly
Ocugen price target lowered to $9.50 from $10 at H.C. Wainwright
1M ago
OCGN
Ocugen to Share Ophthalmic Gene Therapy Progress
Premium
Company Announcements
Ocugen to Share Ophthalmic Gene Therapy Progress
1M ago
8K
OCGN
Ocugen doses first patient in OCU410 trial
PremiumThe Fly
Ocugen doses first patient in OCU410 trial
1M ago
OCGN
Ocugen’s Earnings Call Highlights Risk-Reward Inflection
PremiumCompany Announcements
Ocugen’s Earnings Call Highlights Risk-Reward Inflection
2M ago
OCGN
Ocugen’s Phase 3 Gene Therapy Trial Targets High-Value Dry AMD Market
PremiumCompany Announcements
Ocugen’s Phase 3 Gene Therapy Trial Targets High-Value Dry AMD Market
2M ago
OCGN
Ocugen: Buy Rating Reaffirmed as Cash Runway Extends to 2028 and Ophthalmology Pipeline Advances; $11 Price Target Maintained
PremiumRatings
Ocugen: Buy Rating Reaffirmed as Cash Runway Extends to 2028 and Ophthalmology Pipeline Advances; $11 Price Target Maintained
2M ago
OCGN
Ocugen: Buy Rating Reaffirmed as Late-Stage OCU410/OCU400 Programs Advance; $10 Price Target Maintained
PremiumRatingsOcugen: Buy Rating Reaffirmed as Late-Stage OCU410/OCU400 Programs Advance; $10 Price Target Maintained
2M ago
OCGN
Ocugen reports Q2 EPS (7c), consensus (5c)
Premium
The Fly
Ocugen reports Q2 EPS (7c), consensus (5c)
2M ago
OCGN
Is OCGN a Buy, Before Earnings?
Premium
Pre-Earnings
Is OCGN a Buy, Before Earnings?
2M ago
OCGN
Ocugen granted RMAT designation for OCU410
PremiumThe Fly
Ocugen granted RMAT designation for OCU410
3M ago
OCGN
OCGN Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
OCGN Upcoming Earnings Report: What to Expect?
3M ago
OCGN
Ocugen inks OCU400 licensing deal for MENA
PremiumCompany Announcements
Ocugen inks OCU400 licensing deal for MENA
3M ago
8K
OCGN
Ocugen announces $4M OCU400 license agreement with Roots Pharmaceutical
PremiumThe Fly
Ocugen announces $4M OCU400 license agreement with Roots Pharmaceutical
3M ago
OCGN
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
3M ago
CGC
CPB
Nasdaq, Take-Two, Fastly, Ocugen, Sony Insider Shock
Premium
Weekend Updates
Nasdaq, Take-Two, Fastly, Ocugen, Sony Insider Shock
4M ago
FSLY
NDAQ
Ocugen Stockholders Approve Proposals and Confirm Leadership
Premium
Company Announcements
Ocugen Stockholders Approve Proposals and Confirm Leadership
4M ago
8K
OCGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >